Sign In
Buy INCY
$97.98
+5.74 (+6.22%)
At Close: Jun 03, 2026
Incyte's Ruxolitinib Shows Better Outcomes Regardless Of Organs Affected In GvHD Patients
07:12am, Thursday, 15'th Jul 2021
Incyte Corporation (NASDAQ: INCY) has announced that positive data from the Phase 3 REACH3 study have been published in The New England Journal of Medicine (NEJM). The study is jointly sponsored by
Incyte Announces Positive Phase 3 REACH3 Study Data Published in NEJM for Ruxolitinib (Jakafi®) in Chronic Graft-Versus-Host Disease
05:00pm, Wednesday, 14'th Jul 2021
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #nejm--Incyte Announces Positive Phase 3 REACH3 Study Data Published in NEJM for Ruxolitinib (Jakafi) in Chronic Graft-Versus-Host Disease
Innovent Biologics - Incyte's Pemigatinib Application Under Review In China For Bile Duct Cancer
09:47am, Friday, 09'th Jul 2021
The National Medical Products Administration (NMPA) of China has accepted for review Innovent Biologics Inc's (OTC: IVBIY) marketing application seeking approval for pemigatinib for cholangiocarcin
Incyte's (INCY) Lymphoma Drug Obtains Positive CHMP Opinion
02:17pm, Monday, 28'th Jun 2021
Incyte (INCY) and MorphoSys (MOR) receive positive CHMP opinion for tafasitamab in combination with Revlimid for the treatment of adult patients with relapsed or refractory diffuse large B-cell lympho
REGN vs. INCY: Which Stock Is the Better Value Option?
12:47pm, Monday, 28'th Jun 2021
REGN vs. INCY: Which Stock Is the Better Value Option?
FDA AdCom In Favor Of Delaying Incyte's Retifanlimab Approval In Anal Cancer
09:13am, Friday, 25'th Jun 2021
Members of the Oncologic Drugs Advisory Committee recommended with a 13-4 vote to defer a regulatory decision on Incyte Corporation's (NASDAQ:INCY) retifanlimab until more data can be collected fr
If approved, tafasitamab in combination with lenalidomide would represent an important new therapeutic option for eligible DLBCL patients in the European Union The positive opinion from the CHMP is ba
WILMINGTON, Del. & PLANEGG, Germany & MUNICH--(BUSINESS WIRE)---- $INCY--Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for Adults with Relapsed o
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Outcome of FDA ODAC Meeting Reviewing Retifanlimab as a Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
How This Pharma Company Can Benefit From Its Competitors
05:11am, Sunday, 20'th Jun 2021
Delays in FDA approval for Incyte could spell good news for Sanofi.
Incyte (INCY) Faces Delay in Approval of Atopic Dermatitis Cream
11:17am, Monday, 14'th Jun 2021
Incyte's (INCY) NDA review for ruxolitinib cream for the treatment of atopic dermatitis gets extended.
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Updated Data for Ruxolitinib Cream Accepted for Presentation at the 2021 Revolutionizing Atopic Dermatitis (RAD) Virtual Conference
REGN vs. INCY: Which Stock Should Value Investors Buy Now?
12:47pm, Friday, 11'th Jun 2021
REGN vs. INCY: Which Stock Is the Better Value Option?
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces U.S. FDA Has Extended the New Drug Application Review Period for Ruxolitinib Cream for the Treatment of Atopic Dermatitis
Incyte's (INCY) sNDA Review for Jakafi in GVHD Gets Extended
04:32pm, Wednesday, 09'th Jun 2021
Incyte's (INCY) sNDA review of Jakafi for the indication of steroid-refractory chronic GVHD gets extended by three months.
